Leila Alland Biography and Net Worth

Dr. Alland brings over 25 years of experience in oncology to the leadership of PMV Pharma. Dr. Alland, a pediatric hematologist-oncologist and accomplished physician-scientist, has been working in the biopharmaceutical industry since 2001 to bring novel therapies to patients. Dr. Alland has held leadership positions at Affimed, Tarveda Therapeutics, AstraZeneca, Bristol-Myers Squibb, Novartis, and Schering-Plough, where she worked on a broad range of oncology products from early to late stage development and contributed to multiple successful drug approvals. Dr. Alland obtained her medical degree from New York University School of Medicine, and her B.A. in Biology from the University of Pennsylvania. She completed her residency in Pediatrics at The Children’s Hospital of Philadelphia, and her fellowship in Pediatric Hematology/Oncology at The New York Hospital and Memorial Sloan-Kettering Cancer Center. From 1994 to 2000, Dr. Alland served as Assistant Professor of Pediatrics at Albert Einstein College of Medicine where she was awarded the James S. McDonnell Foundation Scholar Award and pursued basic cancer research while also caring for children with cancer. Dr. Alland sits on the Scientific Advisory Council of Columbia University's Center for Radiological Research and serves as a reviewer for the Cancer Prevention and Research Institute of Texas.

Deepika Jalota, Pharm.D.
Chief Regulatory and Quality Officer

Deepika Jolata photo

Prior to joining PMV Pharma, Dr. Jalota was Vice President, Head of Global Regulatory Strategy, Oncology I at Bayer HealthCare Pharmaceuticals where she was responsible for overseeing the development of global regulatory strategies for several early and late stage oncology projects, including Xofigo®, VITRAKVI® and darolutamide. From 2014-2016 at Bayer, she was responsible for overseeing the development of global regulatory strategies in Ophthalmology and Dermatology, including Eylea®.

Prior to working at Bayer for 12 years, Dr. Jalota was employed with Sanofi-Aventis, Forest Laboratories and Procter and Gamble Pharmaceuticals within various roles across drug development.

Dr. Jalota received her Pharm.D. from University of Florida, College of Pharmacy, and her B.S. in Pharmacy from Rutgers University, Ernest Mario School of Pharmacy.

Binh Vu, Ph.D.
Vice President, Drug Discovery and CMC

Binh Vu photo

Prior to joining PMV Pharma as Director of Research, Dr. Vu was a Research Leader at Roche Nutley where he spent 15 years working in small molecule oncology drug discovery. While at Roche, Dr. Vu was a key contributor to the discovery and development of Nutlins, small molecule MDM2 antagonists which target the p53 pathway. He has extensively published on p53 biology and drug discovery, and is an inventor on 14 issued US patents.

Dr. Vu received a Ph.D. in Chemistry from the University of California, Los Angeles, and completed an NIH Postdoctoral Fellowship at the University of Texas at Austin. He received a B.S. in Chemistry from the University of California, Irvine.

Melissa Dumble, Ph.D.
Vice President, Preclinical Development and Translational Science

Melissa Dumble photo

Prior to joining PMV Pharma, Dr. Dumble was a Research Leader at Bristol-Myers Squibb (BMS, Lawrenceville site) developing small molecules to regulate tumor intrinsic targets that may sensitize cancers to immuno-oncology agents. Before her tenure at BMS she worked at PTC Therapeutics and Enzon Pharmaceuticals leading drug discovery projects in oncology, infectious disease and genetic disorders from lead optimization to clinical trials. Dr. Dumble began her career at GSK Oncology, training as a pharmacologist and working on many of the marketed kinase inhibitors (e.g. VotrientTM, MekinistTM, TafinlarTM). In addition, she led the team of scientists developing an oral AKT inhibitor to clinical trials. Dr. Dumble has co-authored over 20 manuscripts and is an inventor on 5 issued patents.

Dr. Dumble received a Ph.D. in Cell and Molecular Biology from the University of Western Australia, and completed a Postdoctoral Fellowship at Baylor College of Medicine, Houston. Her studies were based on understanding the role of p53 in stem cell dynamics, cancer and aging. She received a B.S. in Biochemistry and Human Biology from the University of Western Australia.

Michael Carulli
Vice President, Finance

Michael Carulli photo

Prior to joining PMV Pharma, Mr. Carulli was an Executive Director of R&D Financial Planning and Analysis at Celgene (now Bristol Myers Squibb) where he oversaw the financial and operational plans for the entire Research and Development organization. Over 10 years at Celgene he held multiple positions with increasing responsibility working closely on the R&D strategy, long range planning, and financial partnering to the Business Development and Alliance Management team. Mr. Carulli was the Chief of Staff to the President of Research & Early Development for 2 years, as well as the R&D finance lead for the Bristol Myers Squibb integration and Otezla divestiture to Amgen.

Combined, Mr. Carulli has over 20 years of financial management experience and has led many process improvement initiatives and implemented several business intelligence technology solutions. He received his MBA from Fordham University.

Robert Ticktin
General Counsel

Robert Ticktin photo

Prior to joining PMV Pharma, Mr. Ticktin was Associate General Counsel, Corporate, at Tesaro, Inc., a development and commercial oncology company (acquired by GSK), where he led corporate legal matters, including SEC reporting, business development and alliance management support.  Prior to Tesaro, he was Senior Vice President and General Counsel at Epirus Biopharmaceuticals, a biosimilar company.  Before his tenure at Epirus, Mr. Ticktin spent 10 years at Amgen Inc., where he held various leadership positions in the legal department.  He began his legal career in New York City at global law firms, Simpson Thacher & Bartlett LLP and Latham & Watkins LLP.  Mr. Ticktin received a B.A. in Economics from The Ohio State University and a J.D. from Fordham University School of Law.

Laura De Leon
Vice President, Head of Clinical Operations

Laura De Leon photo

Laura joined PMV in February 2019 as Head of Clinical Operations with nearly two decades of clinical operations experience in the pharmaceutical industry. Laura has worked in multiple therapeutic areas in all phases of development across company type: large pharma, biotech, medical device, and CRO.

Throughout her career, Laura has held positions of increasing responsibility and leadership in clinical operations and program management at PAREXEL International, Thoratec Corporation, CombinatoRx, Inc., Takeda Oncology, Syndax Pharmaceuticals, EMD Serono, and Seres Therapeutics. Prior to joining PMV, Laura was the Director of Clinical Operations at Seres, responsible for the clinical operations strategy, team management, and oversight of study deliverables for two microbiome therapeutic assets in development including the lead product candidate SER-109 in Clostridioides difficile infection. Laura has extensive monitoring and global trial management experience and has been at the forefront of precision medicine in oncology since joining PMV.

Laura holds a BA in Psychology from Boston College and a MS in Health Product Regulation and Health Policy from Regis College.